• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Canada approves J&J Vision’s drug-eluting contact lens

April 27, 2021 By Sean Whooley

Johnson & Johnson Vision Acuvue TheravisionJohnson & Johnson Vision announced today that it received Health Canada approval for its Acuvue Theravision drug-eluting contact lens.

Jacksonville, Fla.-based J&J Vision’s Acuvue Theravision with Ketotifen is touted as the first and only vision-correcting contact lens that relieves allergic eye itch through drug delivery. The company received Japanese approval for the lens last month.

Acuvue Theravision with Ketotifen contains an H1 histamine receptor antagonist to prevent itchy allergy eyes associated with allergic conjunctivitis, according to a news release.

The company said the product is the first in what it calls an entirely new contact lens category that will improve the patient experience for those with allergic eye itch, as it will continue to help those who wear lenses for vision collection while eliminating the need for allergy eye drops.

“We are proud to mark another step forward in delivering this important innovation to help relieve patients from allergic eye itch while continuing to comfortably wear contact lenses,” J&J Vision global head of R&D Dr. Xiao-Yu Song said in the release. “We look forward to working with additional health authorities to make Acuvue Theravision with Ketotifen available to more patients around the world.”

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance Tagged With: Johnson & Johnson, Johnson & Johnson Vision

IN CASE YOU MISSED IT

  • ApiJect picks up $111M investment from Royalty Pharma, Jefferies
  • FDA approves IND for Ananda Scientific’s PTSD treatment with liquid structure delivery tech
  • Medtronic’s Resolute Onyx drug-eluting stent demonstrates strong safety, efficacy
  • Jabil launches Qfinity reusable auto-injector
  • Labcorp launches at-home collection device for diabetes risk testing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS